SCHEMBL537393

SCHEMBL537393

CCOC(=O)COc1c(CO)c(C(F)(F)F)nn1C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 4/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 2/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALDH1A1 P00352 2/20 0.34
TBXAS1 P24557 1/20 0.34
PKM P14618 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537595 0.83 SMN1; SMN2 (0.38) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL4173041 0.78 SMN1; SMN2 (0.36) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL537606 0.74 SMN1; SMN2 (0.37) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL22381039 0.74 SMN1; SMN2 (0.47) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL4159027 0.74 SMN1; SMN2 (0.34) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL537624 0.73 SMN1; SMN2 (0.33) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL537532 0.71 SMN1; SMN2 (0.35) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL537622 0.71 SMN1; SMN2 (0.35) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL537677 0.70 MEN1 (0.45) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2
SCHEMBL13488613 0.69 KDM4E (0.36) CYP1A2CYP2C9CYP2C19CYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1990336-B1 PROCESS FOR PRODUCTION OF 5-ALKOXY-4-HYDROXYMETHYLPYRAZOLE COMPOUND IHARA CHEMICAL IND CO (JP) 2012-02-08 EP disclosed
US-7812175-B2 Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2010-10-12 US disclosed
US-20090036688-A1 Process for Production of 5-Alkoxy-4-Hydroxymethylpyrazole Compound IHARA CHEMICAL INDUSTRY CO., LTD (JP) 2009-02-05 US disclosed
EP-1990336-A1 PROCESS FOR PRODUCTION OF 5-ALKOXY-4-HYDROXYMETHYLPYRAZOLE COMPOUND Ihara Chemical Industry Co., Ltd. (JP) 2008-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036688-A1 Process for Production of 5-Alkoxy-4-Hydroxymethylpyrazole Compound CYP4F3, ADH5, CYP3A4 CYP1A2 22/4885CYP2C9 81/4885CYP2C19 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.